# Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

> **NCT05411497** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 5 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Autologous MUC1-activated T-cells
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05411497
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-20
- **Primary completion:** 2027-08-18
- **Final completion:** 2027-08-18
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411497, "Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05411497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*